All 9 /Events 0 /In The News 6 /Press Releases 3

NRG Therapeutics Selects Domainex to be its Integrated Drug Discovery Partner for its Biomedical Catalyst Funded Parkinson’s Disease Project

NRG Therapeutics Ltd., an innovative neuroscience company targeting…
30 June 2022/by Webadm

NRG Therapeutics to develop small molecule disease-modifying medicines for debilitating chronic neurodegenerative disorders

Drug Target Review
24 June 2022/by Webadm

£2.68M Award to NRG Therapeutics Supports Work Into Potential DMT

Parkinson’s News Today

Read more
1 June 2022/by Webadm

Award to help NRG Therapeutics develop new Parkinson’s and Motor Neurone Disease treatments

Labiotech

Read more
31 May 2022/by Webadm

NRG receives £2.68m funding boost for neurodegenerative disorders

Pharma Times

Read more
30 May 2022/by Webadm

NRG Therapeutics Announces £2.68M Innovate UK Award to Develop New Medicines to Treat Parkinson’s and Motor Neurone Disease

£2.68 million Biomedical Catalyst (BMC) early-stage award…
30 May 2022/by Webadm

Sticking plaster for brain could beat Parkinson’s disease

Sunday Times

Read more
(behind a paywall)
29 May 2022/by Webadm

NRG Therapeutics awarded £2.68m to fight Parkinson’s and MND

Business Weekly

Read more
22 May 2022/by Webadm

NRG Therapeutics Completes MND Therapeutic Analysis Project with Medicines Discovery Catapult Supported by an Innovate UK EDGE Grant

NRG’s second therapeutic programme to explore brain penetrant…
1 March 2022/by Webadm

Following the path to a new drug, together

Parkinson’s UK Read more

Omega Funds leads £16m Series A round for NRG Therapeutics

Business Weekly

NRG closes £16M series A to fund fight against neurodegenerative diseases

Bioworld Read more

NRG Therapeutics Announces £16 million Series A to Advance Mitochondrial Therapeutics for Parkinson’s and ALS

£16 million Series A led by Omega Funds, to advance disease-modifying…

NRG gearing up for series A to advance brain-penetrant PTP inhibitors

Bioworld Read more (behind a paywall)

NRG Therapeutics and Domainex to collaborate on discovery of small molecules to treat Parkinson’s or motor neurone disease

Cambridge Independent Read more